InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (13 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
13
T+90 hit rate
0%
T+90 mean return
-13.4%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Stein Robert Benjamin, Directeur Exécutif. Officer active across 1 company, notably Mimedx Group, INC.. Cumulatively, 15 filings have been logged. Split: 0 buy · 13 sells. Total volume traded: €846k. Activity tracked since 16 August 2021. The latest transaction was disclosed on 15 May 2023 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations15 total
3,607 shares@ US$6.14650.9% of flowCommon StockSEC:0001376339-23-000031:0
5,869 shares@ US$5.92611.4% of flowCommon StockSEC:0001376339-23-000028:0
51,756 shares@ US$5.341811.5% of flowCommon StockSEC:0001376339-23-000022:0
5,987 shares@ US$3.7440.9% of flowCommon StockSEC:0001628280-23-013697:0
5,996 shares@ US$3.310.8% of flowCommon StockSEC:0001628280-23-011533:0
135,065 shares@ US$4.6226.7% of flowCommon StockSEC:0001376339-23-000007:0
12,355 shares@ US$4.24462.2% of flowCommon StockSEC:0001376339-23-000005:0
19,000 shares@ US$3.4362.9% of flowCommon StockSEC:0001376339-22-000114:0
8,503 shares@ US$4.0391.5% of flowCommon StockSEC:0001376339-22-000110:0
19,500 shares@ US$3.623.1% of flowCommon StockSEC:0001376339-22-000103:0
14,600 shares@ US$3.470.0048% mcap4.6% of flowCommon StockSEC:0001376339-22-000095:0
178,571 shares@ US$4.620.076% mcap72.5% of flowCommon StockSEC:0001376339-22-000038:0
11,672 shares@ US$4.8590.0052% mcap5.0% of flowCommon StockSEC:0001376339-22-000021:0
9,362 shares@ US$11.8534.3% of flowCommon StockSEC:0001376339-21-000097
9,362 shares@ US$11.8530.0094% mcap9.0% of flowCommon StockSEC:0001376339-21-000097:0
15 of 15 declarations
About Stein Robert Benjamin
Robert Benjamin Stein is the EVP of Research and Development and President of Regenerative Medicine at MiMedx Group, Inc. He is responsible for research and development initiatives focused on innovation in the medical field. Robert plays a key role in the strategy for developing new products and improving existing treatments.
